Clinical Trial Update: Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating decitabine in combination with JAK inhibitors (ruxolitinib, fedratinib, or pacritinib) for accelerated or blast-phase myelop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Essential Thrombocythemia
• Myelodysplastic Myeloproliferative Neoplasm
• Myelodysplastic Syndrome
• Myelofibrosis
• Myeloproliferative Neoplasm
• Polycythemia Vera

Drugs mentioned

• Dacogen (decitabine)
• INREBIC (fedratinib hydrochloride)
• Jakafi (ruxolitinib)
• Pacritinib (pacritinib)

Snippet

Sponsor: University of Washington | Conditions: Acute Myeloid Leukemia, Essential Thrombocythemia | Phase 2 | Status: RECRUITING